Politics / Law, Germany

Cross-border exchange of DNA data

19.01.2007

Berlin/Brussels – Seven EU member states, which have already ratified the Prüm Treaty of 2005, have laid down the legal basis for cross-border exchange of enforcement data such as digitalised DNA profiles. The move is intended to strengthen the EU police Europol and to improve judicial cooperation in the era of trans-national threats, such as terrorism, illegal immigration, and crime.
Last December, justice ministers from Germany, Austria, Spain, The Netherlands, Luxembourg, France and Belgium agreed on practical rules on how to manage data exchange with respect to a high degree of data protection. These foresee the use of a hit/no hit procedure without any need for submission of personal data, a time limit for data storage and preconditions for data submission.
The Prüm Treaty is, at present, in force in Germany – the initiator of regulation – Austria and Spain. Germany and Austria have already been exchanging 3,000 DNA profiles since December and Spain is currently in the process of creating the technical preconditions for safe data transfer.
Similar rules are to be transposed into EU law in the first half of 2007, according to the domestic policy work programme “Living Europe Safely” of the German EU presidency. In early January, Wolgang Schäuble, German minister of interior stressed: “The transposition of the Prüm treaty into EU law will be one priority of the German EU presidency.” During an informal meeting of the EU Council in Dresden in mid-January, only 4 member states disagreed. After implementation police would have access to every crime-related DNA database in the European Union.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/cross-border-exchange-of-dna-data-1.html

Product of the week

Products

Events

All Events

Current issue

All issues